Research programme: cancer therapeutics - Valo Health
Latest Information Update: 21 Jan 2021
At a glance
- Originator Valo Health
- Class Antineoplastics
- Mechanism of Action HDAC3 protein inhibitors; Nicotinamide phosphoribosyltransferase inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors; USP28 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer